Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer

Pathology and Oncology Research

Volumn 15, Issue 3, 2009, Pages 359-368

  Akkiprik, Mustafa ^a   Sonmez, Ozgur ^a   Gulluoglu, Bahadir M ^b   Caglar, Hale B ^b   Kaya, Handan ^b   Demirkalem, Pakize ^b   Abacioglu, Ufuk ^b   Sengoz, Meric ^b   Sav, Aydin ^b   Ozer, Ayse ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Haplotype; P53 polymorphisms

Indexed keywords

ARGININE; DNA; PROLINE; PROTEIN P53;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; GENE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; P53 GENE; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; TURKEY (REPUBLIC);

ADULT; BASE SEQUENCE; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73449113685     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-008-9129-6     Document Type: Article

References (37)

1. AM Dunning CS Healey PD Pharoah, et al. 1999 A systematic review of genetic polymorphisms and breast cancer risk Cancer Epidemiol Biomarkers Prev 8 843 854 1:CAS:528:DyaK1MXns1CrtLw%3D 10548311
2. AJ Levine J Momand CA Finlay 1991 The p53 tumour supressor gene Nature 351 453 456 10.1038/351453a0 1:CAS:528:DyaK3MXksVaku7g%3D 2046748
3. JM Nigro SJ Baker AC Preisinger, et al. 1989 Mutations in the p53 gene occur in diverse human tumour types Nature 342 705 708 10.1038/342705a0 1:CAS:528:DyaK3cXkvFyhug%3D%3D 2531845 (Pubitemid 20001591)
4. M Olivier A Langerod P Carrieri, et al. 2006 The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer Clin Cancer Res 12 1157 1167 10.1158/1078-0432.CCR-05-1029 1:CAS:528:DC%2BD28XhsFalt7Y%3D 16489069 (Pubitemid 43342504)
5. M Olivier R Eeles M Hollstein, et al. 2002 The IARC TP53 Database: new online mutation analysis and recommendations to users Hum Mutat 19 607 614 10.1002/humu.10081 1:CAS:528:DC%2BD38XkvVGktro%3D 12007217 (Pubitemid 34556481)
6. A Weston CF Pan HB Ksieski, et al. 1997 p53 haplotype determination in breast cancer Cancer Epidemiol Biomarkers Prev 6 105 112 1:CAS:528: DyaK2sXhs1Kht70%3D 9037561
7. S Wang-Gohrke TR Rebbeck W Besenfelder, et al. 1998 p53 germline polymorphisms are associated with an increased risk for breast cancer in German women Anticancer Res 18 2095 2099 1:STN:280:DyaK1czkt1Cgug%3D%3D 9677474
8. EN Papadakis DN Dokianakis DA Spandidos 2000 p53 codon 72 polymorphisms as a risk factor in the development of breast cancer Mol Cell Bio Res Comm 3 389 392 10.1006/mcbr.2000.0241 1:CAS:528:DC%2BD3cXotlGiuro%3D (Pubitemid 30803131)
9. TG Kalemi AF Lambropoulos M Gueorguiev, et al. 2005 The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece Cancer Lett 222 57 65 10.1016/j.canlet. 2004.11.025 1:CAS:528:DC%2BD2MXjtlans7s%3D 15837541 (Pubitemid 40544847)
10. A Sjalander R Birgander G Hallmans, et al. 1996 p53 polymorphisms and haplotypes in breast cancer Carcinogenesis 17 1313 1316 10.1093/carcin/17.6.1313 1:STN:280:DyaK283otFKqsw%3D%3D 8681448 (Pubitemid 26196343)
11. P Dumont JIJ Leu ACD Pietra, et al. 2003 The codon 72 polymorphic variants of p53 have markedly different apoptotic potential Nat Genet 33 357 365 10.1038/ng1093 1:CAS:528:DC%2BD3sXhsV2ktbc%3D 12567188 (Pubitemid 36278852)
12. MC Marin CA Jost LA Brooks, et al. 2000 A common polymorphism acts as an intragenic modifier of mutant p53 behaviour Nat Genet 25 47 54 10.1038/75586 1:CAS:528:DC%2BD3cXjtFSltr0%3D 10802655 (Pubitemid 30257035)
13. F Gemignani V Moreno S Landi, et al. 2004 A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA Oncogene 23 1954 1956 10.1038/sj.onc.1207305 1:CAS:528: DC%2BD2cXhvFOiurc%3D 14647431 (Pubitemid 38445422)
14. S Peller Y Kopilova S Slutzki, et al. 1995 A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility DNA Cell Biol 14 983 990 10.1089/dna.1995.14.983 1:CAS:528:DyaK28XitFCkug%3D%3D 8534372
15. A Weston MS Wolff A Morabia 1998 True extended haplotypes of p53: indicators of breast cancer risk Cancer Genet Cytogenet 102 153 154 10.1016/S0165-4608(97)00349-X 1:STN:280:DyaK1c3gslOgug%3D%3D 9546072
16. A Sjalander R Birgander A Kivela, et al. 1995 p53 polymorphisms and haplotypes in different ethnic groups Hum Hered 45 144 149 10.1159/000154275 1:STN:280:DyaK2MzktVagtQ%3D%3D 7615299
17. X Wu H Zhao CI Amos, et al. 2002 p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity J Natl Cancer Inst 94 681 690 1:CAS:528:DC%2BD38XktFWlsL4%3D 11983757
18. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer: experience from a long study with long term follow-up Histopathology 19 403 410 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D 1757079
19. SE Singletary C Allred P Ashley, et al. 2002 Revision of the American Joint Committee on Cancer Staging System for breast cancer J Clin Oncol 20 3628 3636 10.1200/JCO.2002.02.026 12202663 (Pubitemid 34983222)
20. R Soong BJ Iacopetta 1997 A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors Mod Pathol 10 252 258 1:STN:280:DyaK2s3isFelsw%3D%3D 9071734
21. SW John G Weitzner R Rozen, et al. 1991 A rapid procedure for extracting genomic DNA from leukocytes Nucleic Acid Res 19 408 10.1093/nar/19.2.408 1:CAS:528:DyaK3MXhtl2itbg%3D 2014181
22. Rockefeller University software database. [Updated 2006 May 11; cited 2007 June 15] Available from: http://linkage. rockefeller.edu/ ott/eh.html
23. B Khadang MJ Fattahi A Talei, et al. 2007 Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women Cancer Genet Cytogenet 173 38 42 10.1016/j.cancergencyto.2006.09.010 1:CAS:528:DC%2BD2sXhtlCks78%3D 17284368 (Pubitemid 46187296)
24. M Franekova P Zubor A Stanclova, et al. 2007 Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population Neoplasma 54 155 161 1:CAS:528:DC%2BD2sXlvF2mu7o%3D 17319790
25. N Buyru H Tigli N Dalay 2003 p53 codon 72 polymorphism in breast cancer Oncol Rep 10 711 714 1:CAS:528:DC%2BD3sXjsVOltLg%3D 12684648
26. A Langerod IRK Bukholm A Bregard, et al. 2002 The TP53 Codon 72 polymorphism may affect the function of TP53 mutation in breast carcinomas but not in colorectal carcinomas Cancer Epidemiol Biomarkers Prev 11 1684 1688 1:CAS:528:DC%2BD3sXmsF2lug%3D%3D 12496062
27. EN Suspitsin KG Buslov MY Grigoriev, et al. 2003 Evidence against involvement of p53 polymorphism in breast cancer predisposition Int J Cancer 103 431 433 10.1002/ijc.10834 1:CAS:528:DC%2BD3sXht1yhsg%3D%3D 12471629 (Pubitemid 36076439)
28. S Wang-Gohrke H Becher R Kreienberg, et al. 2002 Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk or breast cancer by the age of 50 years Pharmacogenetics 12 269 272 10.1097/00008571- 200204000-00012 1:CAS:528:DC%2BD38XnsFKqsb8%3D 11927843 (Pubitemid 34596792)
29. P Wegman O Stal MS Askmalm, et al. 2006 p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients Pharmacogenet Genomics 16 347 351 10.1097/01.fpc.0000204997.84182.69 1:CAS:528:DC%2BD28XjtlCju7c%3D 16609366
30. XL Tan O Popanda CB Ambrosone, et al. 2006 Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients Breast Cancer Res Treat 97 255 262 10.1007/s10549-005-9119-2 1:CAS:528:DC%2BD28XmtFSitro%3D 16331344 (Pubitemid 43945755)
31. S Costa D Pinto D Pereira, et al. 2008 Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer BMC Cancer 8 32 10.1186/1471-2407-8-32 18230179 (Pubitemid 351314953)
32. AN Bartley DW Ross 2002 Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice Arch Pathol Lab Med 126 456 458 11900572
33. P Rolland I Spendlove Z Madjid, et al. 2007 The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer Int J Cancer 120 1311 1317 10.1002/ijc.22430 1:CAS:528:DC%2BD2sXhvVOju7g%3D 17187363 (Pubitemid 46256785)
34. H Yamashita T Toyama M Nishio, et al. 2006 p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer Breast Cancer Res 8 R48 10.1186/bcr1536 16869955 (Pubitemid 44241614)
35. MA Roos GH de Bock J de Vries, et al. 2007 p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast J Surg Res 140 109 114 10.1016/j.jss.2006.10.045 17291532 (Pubitemid 46669545)
36. K Kai R Nishimura N Arima, et al. 2006 p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study Int J Clin Oncol 11 426 433 10.1007/s10147-006-0601-6 1:CAS:528:DC%2BD28XhtlalurzJ 17180510 (Pubitemid 44974395)
37. MD Gammon H Hibshoosh MB Terry, et al. 1999 Cigarette smoking and other risk factors in relation to p53 expression in breast cancer among young women Cancer Epidemiol Biomarkers Prev 8 255 263 1:STN:280:DyaK1M7ovVKqsg%3D%3D 10090304 (Pubitemid 29114204)